Andrew Cheng, Akero Therapeutics CEO
With positive PhII NASH data in tow, Akero opens $175M public offering
It didn’t take long for Akero Therapeutics to open up a public offering after unveiling mid-stage clinical data that sent its stock soaring to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
